Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora reported strong quarterly growth for the period ended March 31, 2026. Revenue reached $78.4 billion, up 3.8% year over year, driven mainly by higher volumes in U.S. Healthcare Solutions, including GLP‑1 therapies for diabetes and weight loss, and growth in European distribution.
Profitability rose sharply. Net income attributable to Cencora increased to $1.64 billion from $718 million, with diluted EPS of $8.40 versus $3.68. Results benefited from a $1.09 billion gain on remeasuring the prior OneOncology stake and continued contributions from the 2025 RCA acquisition.
The balance sheet reflects aggressive investment. Total assets grew to $81.7 billion and goodwill to $16.45 billion, largely from the $7.39 billion OneOncology acquisition. Long‑term debt rose to $12.18 billion after multiple new term loans and senior notes, while cash and cash equivalents declined to $2.18 billion. Operating cash flow was a use of $966.5 million as working capital and acquisition‑related items absorbed cash.
Cencora reported solid fiscal 2026 second-quarter results with revenue of $78.4 billion, up 3.8% year-over-year. GAAP diluted EPS jumped to $8.40 from $3.68, boosted by a $1.1 billion gain tied to the OneOncology acquisition, while adjusted diluted EPS rose 7.5% to $4.75.
The company raised its fiscal 2026 adjusted EPS guidance to $17.65–$17.90 from $17.45–$17.75 and now expects about $3.0 billion in adjusted free cash flow. Management also plans to repurchase $1 billion of shares by the end of calendar 2026 and declared a quarterly dividend of $0.60 per share.
Tyler Lauren M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Lauren M. Tyler received an equity award rather than making an open-market trade. On May 1, 2026, Tyler was granted 99 shares of Common Stock, reported at $304.00 per share, under the company’s Non-Employee Director Compensation Program.
The award represents restricted stock units granted in lieu of a $30,000 quarterly cash retainer, with actual receipt of the shares deferred until Tyler’s board service ends. After this grant, Tyler directly holds 3,809 shares of Cencora common stock, indicating this is a routine component of director compensation rather than a discretionary stock purchase or sale.
Cooper Ellen reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Ellen Cooper received an equity-based compensation award rather than cash. She was granted 99 shares of Common Stock on May 1, 2026, recorded at $304.00 per share, as a grant or award transaction.
According to the footnote, this is a grant of restricted stock units received in lieu of a $30,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program, with receipt of the shares deferred until she ceases board service. Following this award, she directly holds 796 shares of Cencora common stock.
NALLY DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Dennis M. Nally received an award of 116 shares of common stock on May 1, 2026. The shares were issued in lieu of a $35,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program.
Following this compensation grant, Nally directly holds 13,075 shares of Cencora common stock.
Cencora Inc reported that Vanguard Capital Management beneficially owned 14,210,260 shares of common stock, representing 7.3% of the class as reported on 03/31/2026. The filing shows sole voting power for 1,896,801 shares and sole dispositive power for 14,210,260 shares. The Schedule 13G filing was signed on 04/29/2026.
Krikorian Lazarus reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that SVP & Chief Accounting Officer Lazarus Krikorian received a grant of 3,936 Restricted Stock Units on April 1, 2026. According to the filing, these Restricted Stock Units were received for no consideration and vest in full on April 1, 2028. Following this grant, Krikorian holds a total of 3,936 Restricted Stock Units directly.
The Vanguard Group filed Amendment No. 20 to a Schedule 13G/A reporting its position in Cencora Inc common stock. The filing states an amount beneficially owned: 0 shares representing 0% of the class. The amendment explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report separately in reliance on SEC Release No. 34-39538.
Cencora, Inc. has signed a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, expanding its Retina Consultants of America network. The affiliated retina physicians are expected to join RCA, strengthening Cencora’s position in specialized eye care.
Cencora expects the deal to be slightly accretive to adjusted diluted EPS in the first 12 months after closing, net of financing costs. The transaction is subject to customary closing conditions and required regulatory approvals. Cencora reaffirmed its fiscal 2026 financial guidance, which currently does not assume the transaction will close within that fiscal year.
Cencora, Inc. has announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer, effective June 30, 2026. He will assist with the search for a successor and continue in an advisory capacity through the end of 2026 to support a smooth leadership transition.
Cleary, age 62, has served as Cencora’s CFO since November 2018 and previously led MWI Veterinary Supply as CEO for over a decade before joining Cencora in 2015. The company stated that his retirement is not related to any disagreement over operations, policies, or practices.
Alongside the leadership news, Cencora reaffirmed its previously issued adjusted diluted EPS guidance for fiscal year 2026, maintaining a range of $17.45 to $17.75. Cencora highlights its scale as a global pharmaceutical solutions organization with more than $300 billion in annual revenue and over 51,000 team members worldwide.